Acute Myeloid Leukemia as a Trigger for Hemolytic-Uremic Syndrome

Acute myeloid leukemia (AML) has not been identified as a cause of secondary hemolytic-uremic syndrome (HUS). This case report describes a woman who developed severe HUS at the time of AML diagnosis and responded favorably to initial treatment with eculizumab, which stabilized her condition and allo...

Full description

Saved in:
Bibliographic Details
Published in:Journal of clinical medicine 2024-10, Vol.13 (21), p.6468
Main Authors: El Bachouti, Jonas, Domínguez-Guasch, Anna, Arce, Yolanda, Oñate, Guadalupe, Marco, Helena, Diaz, Montserrat, Guirado, Lluís, Torra, Roser, Barros, Xoana
Format: Article
Language:English
Subjects:
Anemia
Antibiotics
Biopsy
Blood
Bone marrow
Case Report
Chemotherapy
Creatinine
Cytomegalovirus
Disease
E coli
Haplotypes
Hematology
Hemodialysis
Hemolytic-uremic syndrome
Kidneys
Kinases
Leukemia
Mutation
Patients
Pneumonia
Remission (Medicine)
Risk factors
Thrombocytopenia
Toxins
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Acute myeloid leukemia (AML) has not been identified as a cause of secondary hemolytic-uremic syndrome (HUS). This case report describes a woman who developed severe HUS at the time of AML diagnosis and responded favorably to initial treatment with eculizumab, which stabilized her condition and allowed for treatment of the AML. After one year, with stable renal function and genetic studies reported as normal, eculizumab was successfully discontinued. The prompt use of eculizumab was critical to the patient's survival and improvement in renal function, highlighting the efficacy of early eculizumab treatment in secondary HUS.
ISSN:2077-0383
2077-0383
DOI:10.3390/jcm13216468